Immutep Limited American Depositary Shares IMMP

Immutep Ltd is a clinical-stage biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

IMMP hizo una agrupación de acciones (split inverso) de 1:20 el 28 de septiembre de 2026: cada 20 acciones se juntaron en una. Bajó la cantidad de acciones y subió su precio, pero no el valor total de la inversión.

• GlobeNewswire Inc. 30 sept

  Head and Neck Squamous Cell Carcinoma (HNSCC) - Market Insights, Epidemiology, and Market Forecast - 2036 | Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape Care

  The HNSCC market is projected to grow from $850 million in 2025 to $2.56 billion by 2036 (10.5% CAGR), driven by HPV-targeted vaccines, checkpoint inhibitors, and biomarker-led patient selection. The US will remain the largest market at $2.082 billion. Key therapies include KEYTRUDA and OPDIVO, with emerging candidates like petosemtamab and amivantamab showing promise in clinical development.

  

• GlobeNewswire Inc. 21 jul

  Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight

  The head and neck squamous cell carcinoma (HNSCC) market is expected to grow at a 10.5% CAGR from 2026-2036, driven by rising cancer incidence, increased adoption of immunotherapies, and the launch of emerging novel treatments. The market was valued at USD 850 million in 2025 across seven major markets, with KEYTRUDA currently generating the highest revenue among HNSCC therapies.

  

• GlobeNewswire Inc. 13 jul

  Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight

  The head and neck squamous cell carcinoma (HNSCC) market is expected to grow at a CAGR of 10.5% from 2026-2036, driven by rising cancer incidence, increased adoption of immunotherapies, and the launch of emerging novel treatments. The market was valued at USD 850 million in 2025 across seven major markets, with KEYTRUDA currently generating the highest revenue. Multiple companies are advancing innovative therapies targeting HPV16-positive HNSCC and other molecular pathways.

  

• GlobeNewswire Inc. 1 jul

  Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Graphic Packaging Holding Company (GPK), Immutep Limited (IMMP), and Phreesia, Inc. (PHR) Announced by Holzer & Holzer, LLC

  Holzer & Holzer, LLC announced lead plaintiff deadlines for shareholder class action lawsuits against Graphic Packaging Holding Company, Immutep Limited, and Phreesia, Inc. The lawsuits allege materially false statements and/or failure to disclose material facts regarding inventory management, clinical trial status, and long-term growth outlook respectively. Investors who purchased shares during specified periods and suffered losses are encouraged to seek lead plaintiff status by the July 6-13, 2026 deadlines.

  

• GlobeNewswire Inc. 29 jun

  Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Graphic Packaging Holding Company (GPK), Immutep Limited (IMMP), and Phreesia, Inc. (PHR) Announced by Holzer & Holzer, LLC

  Holzer & Holzer, LLC announced lead plaintiff deadlines for shareholder class action lawsuits against multiple companies including Graphic Packaging Holding Company, Immutep Limited, and Phreesia, Inc. The lawsuits allege materially false or misleading statements regarding inventory management, clinical trial prospects, and growth outlook respectively. Investors who purchased shares during specified periods and suffered losses are encouraged to seek lead plaintiff status.